COMMUNIQUÉ DE PRESSE publié le 24/05/2023 à 12:00, il y a 3 années 4 mois Tryp Therapeutics Submits Investigational New Drug (IND) Application to US FDA for Planned Phase 2a Clinical Trial in Patients With IBS at Massachusetts General Hospital
COMMUNIQUÉ DE PRESSE publié le 27/04/2023 à 12:00, il y a 3 années 5 mois Tryp Therapeutics Announces Closing of Oversubscribed Private Placement of Secured Convertible Debentures for Gross Proceeds of AUD$2,400,000
COMMUNIQUÉ DE PRESSE publié le 12/04/2023 à 22:00, il y a 3 années 5 mois Tryp Therapeutics Announces Private Placement of Secured Convertible Debentures for Gross Proceeds of a Minimum of AUD$2,000,000
COMMUNIQUÉ DE PRESSE publié le 04/04/2023 à 12:00, il y a 3 années 6 mois Tryp Therapeutics Completes Psychotherapy Training for Planned Phase 2a Clinical Trial at Massachusetts General Hospital
COMMUNIQUÉ DE PRESSE publié le 05/01/2023 à 13:00, il y a 3 années 9 mois Tryp Therapeutics Announces Interim Results for Its Phase II Clinical Trial for the Treatment of Binge Eating Disorder With Psilocybin-Assisted Psychotherapy
COMMUNIQUÉ DE PRESSE publié le 03/01/2023 à 13:00, il y a 3 années 9 mois Tryp Therapeutics and Massachusetts General Hospital Sign Letter of Intent for Clinical Study Investigating the Use of Psilocybin-Assisted Psychotherapy for the Treatment of Patients Suffering From Irritable Bowel Syndrome (IBS)
Publié le 05/10/2026 à 22:12, il y a 31 minutes AXA - Elimination of the dilutive impact of Shareplan 2026
Publié le 05/10/2026 à 22:12, il y a 31 minutes AXA - Elimination de l'effet dilutif de l'opération Shareplan 2026
Publié le 05/10/2026 à 18:13, il y a 4 heures 30 minutes Disclosure of shares outstanding and voting rights - 05.10.2026
Publié le 05/10/2026 à 18:13, il y a 4 heures 30 minutes Déclaration nombre d'actions et droits de vote - 05.10.2026
Publié le 05/10/2026 à 18:00, il y a 4 heures 43 minutes LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 30 septembre 2026
Publié le 05/10/2026 à 22:30, il y a 13 minutes EV Nickel Announces Formation of Wholly Owned Subsidiary to Advance Nickel Bioleaching Technology and Canadian Nickel Supply Chain
Publié le 05/10/2026 à 14:45, il y a 7 heures 58 minutes NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives
Publié le 05/10/2026 à 14:30, il y a 8 heures 13 minutes Hillcrest and Equipmake Expand Partnership Talks to Include Commercial Licensing of ZVS Technology
Publié le 05/10/2026 à 14:30, il y a 8 heures 13 minutes Solitario CEO to Present at John Tumazos Very Independent Research, LLC
Publié le 05/10/2026 à 14:00, il y a 8 heures 43 minutes Tectonic Metals Appoints Eduard Epshtein as CFO, Bolstering Executive Team for Next Stage of Growth
Publié le 05/10/2026 à 22:25, il y a 18 minutes LumApps Named a Leader in 2026 Gartner® Magic Quadrant™ for Intranet Packaged Solutions
Publié le 05/10/2026 à 22:05, il y a 38 minutes AMPERA SUBMITS COMPREHENSIVE ENGAGEMENT PLAN TO THE U.S. NUCLEAR REGULATORY COMMISSION
Publié le 05/10/2026 à 21:10, il y a 1 heure 33 minutes Shelly Group Board of Directors considers EUR 70.00 offer price fair and supports Schneider Electric’s voluntary public tender offer
Publié le 05/10/2026 à 21:05, il y a 1 heure 38 minutes EQS-Adhoc: Shelly Group SE: Board of Directors with positive opinion on the registered voluntary public tender offer by Schneider Electric SE
Publié le 05/10/2026 à 20:15, il y a 2 heures 28 minutes EQS-Adhoc: United Internet AG participates in capital increase against contributions in kind at 1&1 AG
